Fezolinetant and Bone Mineral Density: Current Evidence and Clinical Insights

EP: 1.Impact of Menopause on Bone Health and Fracture Risk

EP: 2.Therapies for Vasomotor Symptoms and Their Effects on Bone Mineral Density

EP: 3.Neurokinin Therapies for VMS: MOAs and Potential Bone Health Implications

EP: 4.OASIS-3 Trial and Bone Mineral Density Subanalysis: Design, Methods, and End Points

EP: 5.BMD Biomarker Outcomes With Elinzanetant vs Placebo: Clinical Relevance and Implications

EP: 6.OASIS-3 Subanalysis: Weight and Muscle Mass Outcomes With Elinzanetant

EP: 7.Key Takeaways and Clinical Implications From the OASIS-3 Subanalysis

Now Viewing

EP: 8.Fezolinetant and Bone Mineral Density: Current Evidence and Clinical Insights

EP: 9.Fezolinetant’s Impact on Weight and Muscle

EP: 10.Bone Density’s Role in VMS Treatment and Neurokinin Therapy

Video content above is prompted by the following:

Fezolinetant, another neurokinin-3 receptor antagonist, has been evaluated in 52-week clinical studies involving postmenopausal women with moderate to severe vasomotor symptoms. Current available data indicates that fezolinetant has a neutral effect on bone density and bone health, neither improving nor worsening skeletal outcomes.

This neutral bone health profile distinguishes fezolinetant from elinzanetant, which showed potential bone benefits in the OASIS-3 trial. The difference may relate to the specific receptor targeting, as fezolinetant acts solely on NK-3 receptors while elinzanetant targets both NK-1 and NK-3 receptors.

The neutral bone health effects of fezolinetant, while not providing additional skeletal benefits, may still represent an acceptable profile for women primarily seeking vasomotor symptom relief without estrogen therapy. This positions fezolinetant as a viable option for symptom management while maintaining bone health status quo.